Biotech hits the brakes on their PhIII pivotal for a lead antibiotic as investigators track a high rate of kidney injuries
The Swiss biotech Polyphor is back with a fresh cautionary tale about the antibiotics sector.
Just days away from its first anniversary of an IPO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
